Towards an early RT-QuIC-based diagnostic biomarker for Lewy body-related synucleinopathies

Francesca Magrinelli, MD¹,², Michele Tinazzi, MD, PhD², Kailash P. Bhatia, MD, DM, FRCP¹

¹ Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom
² Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy

Corresponding author:
Francesca Magrinelli, MD
Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology
Queen Square, London WC1N 3BG, United Kingdom
E-mails: f.magrinelli@ucl.ac.uk; francesca.magrinelli@univr.it

Word count:
Abstract: N/A
Text: 500 words
References: 10
Graphics (Tables/Figures): 0/0

Running title:
CSF RT-QuIC in α-synucleinopathies

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/mdc3.13050

This article is protected by copyright. All rights reserved.
Key words:

α-synuclein; biomarker; Parkinson’s disease; multiple system atrophy; RT-QuIC


Synucleinopathies are neurodegenerative diseases pathologically characterized by aggregates of α-synuclein protein in selectively vulnerable neurons and/or glia. These include neuronal Lewy bodies (LB) and Lewy neurites in Parkinson’s disease (PD), dementia with LB (DLB), and PD dementia, and predominantly oligodendroglial cytoplasmic inclusions in multiple system atrophy (MSA). Isolated REM sleep behavior disorder (iRBD) and pure autonomic failure (PAF) are often underpinned by α-synuclein pathology, sometimes revealing themselves as prodromal stages of the above-mentioned disorders in retrospect.

The self-propagation of misfolded proteins assembling into seeds that induce normal like proteins to misshape and aggregate was first recognized as mechanism of neurotoxicity in prion diseases. Increasing evidence supports the prion-like behaviour of other proteins in neurodegeneration, including amyloid-β, tau, and α-synuclein. Therefore, detecting protein aggregates in easily accessible biospecimens represents a promising diagnostic avenue, especially in synucleinopathies which can be difficult to clinically differentiate in early stages and lack specific PET radiotracers. Moreover, since the prion-like process may precede their clinical onset by years or decades, iRBD and PAF are potential targets for an early biochemical diagnosis of synucleinopathies.
Real-Time Quaking-Induced Conversion (RT-QuIC) is a high-sensitive amplification assay to detect the seeding activity of protein aggregates in biospecimens at the expense of a substrate (i.e., the recombinant protein) under shaking conditions, which is monitored by thioflavin T fluorescence. RT-QuIC has first been validated in sporadic Creutzfeldt-Jacob disease, being now included in its diagnostic criteria, and recently explored in synucleinopathies.

Following an established protocol, Rossi et al. performed CSF α-synuclein RT-QuIC in a large cohort of: 1) neuropathologically verified cases of LB-positive and negative dementia, atypical parkinsonism, and LB-negative controls; and 2) clinically diagnosed cases of PD, atypical parkinsonism, dementia, iRBD, and PAF. The assay accurately detected α-synuclein seeding activity across LB-related synucleinopathies (i.e., PD, DLB, iRBD, and PAF), with an overall sensitivity of 95.3% (100% in definite DLB and iRBD) and an overall specificity of 98% against cases lacking LB on neuropathology. Intriguingly, negative RT-QuIC results were found in almost all MSA cases, one iRBD case with subsequent phenocconversion to MSA, and one PAF case showing normal adrenergic cardiac innervation on MIBG-SPECT, as observed in MSA. Finally, quantification of α-synuclein seeding activity through fluorescence analysis did not discriminate among LB-related clinical syndromes.

Besides supporting the prion-like nature of LB-related synucleinopathies, this study demonstrates that α-synuclein RT-QuIC provides an accurate and reliable biomarker for these disorders in the largest cohort hitherto investigated. It also proves that RT-QuIC detects α-synuclein seeding activity in prodromal syndromes, allowing early diagnosis of synucleinopathy and identification of candidates for disease-modifying trials. Interpretation of negative assay results in most MSA cases is arguable. Although it might confirm that MSA and LB-related syndromes are associated with different
conformational α-synuclein strains, further research needs to clarify whether different RT-QuIC set-ups may detect α-synuclein seeding activity in MSA, thus differentiating synucleinopathies.

In conclusion, these findings endorse the inclusion of an RT-QuIC-based biomarker in diagnostic criteria for LB-related synucleinopathies and promote studies to test α-synuclein RT-QuIC of other biospecimens and as progression/prognostic tool.
Acknowledgments

None

Author Roles

1. Research project: A. Conception, B. Organization, C. Execution;

Francesca Magrinelli: 1A, 2A, 2B, 3A
Michele Tinazzi: 2C, 3B
Kailash P. Bhatia: 1A, 2C, 3B

Disclosures

Funding Sources and Conflict of Interest:

No specific funding was received for this work. The authors declare that there are no conflicts of interest relevant to this work.

Financial Disclosures for the previous 12 months:

FM is supported by the European Academy of Neurology (EAN) Research Fellowship 2020.

MT reports no disclosures.

KPB has received grant support from Welcome/MRC, NIHR, Parkinson’s UK and EU Horizon 2020. He receives royalties from publication of the Oxford Specialist Handbook Parkinson’s Disease and Other Movement Disorders (Oxford University Press, 2008), of Marsden’s Book of Movement Disorders (Oxford University Press, 2012), and of Case Studies in Movement Disorders–Common and
uncommon presentations (Cambridge University Press, 2017). He has received honoraria/personal compensation for participating as consultant/scientific board member from Ipsen, Allergan, Merz and honoraria for speaking at meetings and from Allergan, Ipsen, Merz, Sun Pharma, Teva, UCB Pharmaceuticals and from the American Academy of Neurology and the International Parkinson’s Disease and Movement Disorders Society.

**Ethical Compliance Statement**

We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. The authors confirm that the approval of an institutional review board was not required for this work. The authors confirm that no patient consent was required for this work.
References


